UBAM (CH) – SWISS EQUITY

Quarterly Comment

The product range UBAM (CH) must be distributed only in Switzerland to Professional Investors

Market Comment

- Supported by optimism around a softer landing in the US, the AI hype and soon to come interest rate cuts, equity markets continued their climb in Q1 2024, with many of the main indices making new all-time highs. In March, performance drivers started to broaden with energy and banks contributing positively, as investors were looking for attractively priced areas of the market away from the diverging “Mag 7”. The MSCI AC World rose +8.1% over the quarter, with Japanese equities up +17.3%, US equities +10.6%, Swiss equities +6.0%, European equities +7.6%, and Emerging Market equities +2.1% (performances as of 28.03.2024, in local currencies).
- US GDP growth for Q4 23 came in slightly above estimates at 3.4% qoq but showed some slowdown from the previous quarter. Activity is expected to moderate in Q1 2024, but average growth for the full year should remain in a 2%-2.5% range after 2.3% in 2023. This would support the soft-landing scenario as US consumers continue to benefit from a tight employment market. The US Fed announced no change in key rates during their March meeting, as inflation remained elevated coupled with solid activity and strong labor indicators. The US yearly inflation trend increased for end of February from 3.1% to 3.2%. EPS growth expectations for US equities stand at 10% for 2024, with valuation edging slightly higher to 20.9x fwd PE ratio. This rerating continues to be mainly driven by the large cap tech companies, that are still gaining in weight in the indices, and boast high profitability and earnings growth. Nevertheless, the dominant Magnificent 7 trade continued to show divergences with Tesla and Apple posting losses YTD.
- In a surprise move against most predictions, the Swiss National Bank lowered its key rate from 1.75% to 1.5% in March, as inflation stabilized well below its 2% target since June 2023. The manufacturing PMI for Switzerland came in higher than expected and the prior print, at 45.2, but still below the 50 level. Business sentiment had notably improved on production, new orders, and employment. The leading KOF indicator remained stable for end of March at 101.5, compared to 101.6 for the prior month. EPS growth expectations for Swiss equities still stand at 10% for 2024, with an 18.8x fwd PE ratio. Compared to 9% EPS growth expectations for global equities at 17.9x fwd PE ratio, and to US equities, Swiss equities continue to offer attractively priced investment opportunities for 2024.
- Over Q1 2024, Healthcare, Financials and Industrials were the best contributing sectors of the SPI, while Consumer Staples, IT and Utilities posted negative returns. In terms of single names, Lonza, Novartis and Richemont were the best individual contributors while Nestlé, Roche and Kuehne + Nagel were the largest detractors.

All performance figures are given gross of fees. Past performance is not a guide to current or future returns. See full disclaimer at the end of the document.

Performance Review

- Over Q1 2024, UBAM (CH) - Swiss Equity delivered +7.3% in gross performance, versus +6.0% for the SPI. Stock selection, notably in Industrials and Healthcare, was the major performance contributor over the quarter. On the other hand, sector allocation detracted from relative performance, especially the underweight in Consumer Discretionary.
- During Q1, the biggest contributors to relative performance were the overweights in Accelleron and Lonza as well as the the underweight in Nestlé (+37bps, +26bps and +26bps respectively). Accelleron finished the quarter up +28.6%, as it saw a couple of analyst estimate upgrades and delivered FY23 results that beat on all items. Lonza’s share price gained +52.7% as the company posted FY23 results above expectations and reiterated its 2024 and mid-term guidance. A proposed bill in the US that would prohibit federal funding of biotechnology equipment or services produced or provided by Chinese biotechnology service providers, as well as Lonza’s acquisition of the Roche Vacaville manufacturing site further lifted the stock over the quarter. Nestlé lost -1.8% over the quarter after posting Q4 organic sales growth below expectations as the world's biggest packaged food company continued to hike prices, prompting some shoppers to turn to competing products. In addition, the 2024 organic growth guidance came in at the lower end of consensus expectations.
- The main detractors to relative performance over the period were the absence of exposure to Richemont, Holcim and SGS (-53bps, -42bps and -11bps respectively). After a muted start into the year Richemont’s stock changed direction mid-January, as the company reported stronger than expected holiday sales in the US and China, alleviating concerns over a cool down in demand for luxury goods. While the rally came to a halt mid-March on weaker Swiss watch exports and a broker downgrade, the stock still finished the quarter up +18.8%. Holcim’s share price appreciated by +23.7% as the company announced a spin-off of its North American business, delivered FY23 results as well as 2024 guidance above expectations, and announced a CHF 1bn share buyback. SGS rose +20.6% after the company announced that CFO Géraldine Picaud will take over as CEO and laid out new 2027 targets at a strategy update at the end of January.

Portfolio Activity

- Over Q1, the underweight position in Julius Baer was sold on continued worries around the company’s compliance and risk management practices. The team also completed the sale of Aluflexpack, on continued slowing sales momentum and high capital expenditure for the construction of a new factory. On the other hand, the team participated in the IPO of Galderma Group. Galderma is a leading dermatology company with a science-based portfolio of brands and services that span the full spectrum of the self-care dermatology market through injectable aesthetics, dermatological skincare, and therapeutic dermatology. The position in Tecan was reduced after preliminary figures published early January suggested that revenue expectations could be too optimistic for 2024, despite improved margin expectations.

Outlook

- Given the current market concentration levels particularly around US tech names, investors should factor in the risks of a negative market surprise linked to geopolitics and elections, interest rate moves or AI related results. We believe that investors should privilege diversified sources of performance for 2024, and Swiss equities are well positioned with a stable political and macro-economic backdrop, as well as a proactive central bank that has started the easing cycle.
- The team continues to see a favourable environment for Swiss companies in 2024, supported by the expected global GDP growth recovery and alleviating FX pressure on earnings after the SNB's move to cut rates. The global recovery in trade and manufacturing, as well as continued reshoring activity, could provide a tailwind for the Industrials sector. The Swiss small and mid-cap space – with close to 30% exposure to the Industrials sector – should be poised to benefit from this dynamic, supported by attractive valuation levels relative to the larger market cap segment. The Swiss Equity strategy maintains its focus on visible levels of value creation, while also being exposed to attractive growth opportunities in the small and mid-cap space.

This is a marketing document and is intended for informational and/or marketing purposes only. **It is intended to be used only by the person(s) to whom it was delivered.** It may not be reproduced (in whole or in part) or delivered, given, sent or in any other way made accessible, to any other person without the prior written approval of Union Bancaire Privée, UBP SA or any entity of the UBP Group (UBP). This document reflects the opinion of UBP as of the date of issue. This document is for distribution only to persons who are Professional clients in Switzerland or Professional clients or an equivalent category of investor as defined by the relevant laws (all such persons together being referred to as “Relevant Persons”).

This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. It is not intended for distribution, publication, or use, in whole or in part, in any jurisdiction where such distribution, publication, or use would be unlawful, nor is it directed at any person or entity at which it would be unlawful to direct such a document. In particular, this document may not be distributed in the United States of America and/or to US persons (including US citizens residing outside the United States of America). This document has not been produced by UBP’s financial analysts and is not to be considered financial research. It is not subject to any guidelines on financial research and independence of financial analysis. Reasonable efforts have been made to ensure that the content of this document is based on information and data obtained from reliable sources. However, UBP has not verified the information from third sources in this document and does not guarantee its accuracy or completeness. UBP makes no representations, provides no warranty and gives no undertaking, express or implied, regarding any of the information, projections or opinions contained herein, nor does it accept any liability whatsoever for any errors, omissions or misstatements. The information contained herein is subject to change without prior notice. UBP gives no undertaking to update this document or to correct any inaccuracies in it which may become apparent. This document may refer to the past performance of investment interests. **Past performance is not a guide to current or future results.** The value of investment interests can fall as well as rise. Any capital invested may be at risk and investors may not get back some or all of their original capital. Any performance data included in this document does not take into account fees, commissions, and expenses charged on issuance and redemption of securities, nor any taxes that may be levied. Changes in exchange rates may cause increases or decreases in investors’ returns. All statements other than statements of historical fact in this document are “forward-looking statements”. Forward-looking statements do not guarantee future performances. The financial projections included in this document do not constitute forecasts or budgets; they are purely illustrative examples based on a series of current expectations and assumptions which may not eventuate. The actual performance, results, financial condition and prospects of an investment interest may differ materially from those expressed or implied by the forward-looking statements in this document as the projected or targeted returns are inherently subject to significant economic, market and other uncertainties that may adversely affect performance. UBP also disclaims any obligation to update forward-looking statements, as a result of new information, future events or otherwise. The contents of this document should not be construed as any form of advice or recommendation to purchase or sell any security or funds. It does not replace a prospectus or any other legal documents, which can be obtained free of charge from the registered office of a fund or from UBP. The opinions herein do not take into account individual investors’ circumstances, objectives, or needs. Each investor must make their own independent decision regarding any securities or financial instruments mentioned herein and should independently determine the merits or suitability of any investment. In addition, the tax treatment of any investment in the fund(s) mentioned herein depends on each individual investor’s circumstances. Investors are invited to carefully read the risk warnings and the regulations set out in the prospectus or other legal documents and are advised to seek professional counsel from their financial, legal and tax advisors. The tax treatment of any investment in a Fund depends on the investor’s individual circumstances and may be subject to change in the future. This document should not be deemed an offer nor a solicitation to buy, subscribe to, or sell any currency, funds, products, or financial instruments, to make any investment, or to participate in any particular trading strategy in any jurisdiction where such an offer or solicitation would not be authorised, or to any person to whom it would be unlawful to make such an offer or solicitation. Telephone calls to the telephone number stated in this presentation may be recorded. UBP will assume that, by calling this number, you consent to this recording.

Pursuant to Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability-related disclosures in the financial services sector (the “Disclosures Regulation” or “SFDR”), funds are required to make certain disclosures. Funds falling under the scope of Article 6 of the SFDR are those which have been deemed not to pursue an investment approach that explicitly promotes environmental or social characteristics or has sustainable investment as their objective. The investments underlying this financial product do not take into account the EU criteria for environmentally sustainable economic activities. Notwithstanding this classification, the Investment Managers may take account of certain sustainability risks as further described in the fund’s prospectus. Funds falling under the scope of Articles 8 or 9 of the SFDR are those subject to sustainability risks within the meaning of the SFDR. The sustainability risks and principal adverse impacts as stipulated in the SFDR are described in the prospectus. In addition, unless otherwise specified, all funds apply the UBP Responsible Investment policy, which is available on **https://www.ubp.com/en/investment-expertise/responsible-investment**

UBP relies on information and data collected from ESG third party data providers which may prove to be incorrect or incomplete. Although UBP applies a proven selection process of such third-party providers, its processes and proprietary ESG methodology may not necessarily capture appropriately the ESG risks. Indeed, data related to sustainability risks or PAI are today either not available or not yet systematically and fully disclosed by issuers, may be incomplete and may follow various methodologies. Most of the ESG factors information is based on historical data that they may not reflect the future ESG performance or risks of the investments.

ESG information providers: Although Union Bancaire Privée, UBP SA, ESG information providers (the “ESG Parties”) obtain information from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties makes any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Any subscriptions not based on the funds’ latest prospectuses with integrated fund contracts, KIDs, annual or semi-annual reports (the “Funds’ Legal Documents”) shall not be acceptable. The Funds’ Legal Documents may be obtained free of charge from Gérifonds SA, 2 rue du

Maupas, 1002 Lausanne, Switzerland, or from BCV,14 place Saint Francois ,1003 Lausane, Switzerland or from Union Bancaire Privée, UBP SA, 96–98 rue du Rhône, P.O. Box 1320, 1211 Geneva 1, Switzerland.

This content is being made available in the following countries:

Switzerland: UBP is authorised and regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA). The head office is Union Bancaire Privée, UBP SA, 96-98 rue du Rhône, P.O. Box 1320, 1211 Geneva 1, Switzerland.**ubp@ubp.com** | **www.ubp.com**